Thank you, Julissa. 2025 was a truly transformative year for Verastem as we transition to a commercial stage company following our FDA approval of the first treatment specifically for KRAS-mutated ...
Verastem (NASDAQ:VSTM) executives said the company’s transition to a commercial-stage business accelerated in 2025 following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results